{"id":"9bd442d4-a901-5412-b52d-6335f4c5ba82","stable_key":"e13b03e1-a614-543a-ac1b-97df18cfe30d:iron-fcm-intact-fgf23","predicate":"increased","statement":"Ferric carboxymaltose increased biologically active FGF23 in the substudy; the mean within-person increase at the week-two peak was approximately 303%, versus 10% with ferumoxytol.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"baf4bf6d-4c6f-51d3-948d-fc1dbd3335d0","mechanism_event_label":"The treatment changed a hormone that controls phosphate handling.","subject":{"id":"3f2beafe-a8b7-5242-ab5a-7e46ee7b9913","slug":"ferric-carboxymaltose","display_name":"Ferric carboxymaltose","entity_type_key":"chemical_species"},"object":{"id":"fe53ea97-98c6-5545-a40f-d4e43129d32d","slug":"circulating-intact-fgf23","display_name":"Circulating biologically active intact FGF23","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"baf4bf6d-4c6f-51d3-948d-fc1dbd3335d0","stable_key":"e13b03e1-a614-543a-ac1b-97df18cfe30d:iron-fcm-intact-fgf23-event","event_type":"biochemical_relationship","label":"The treatment changed a hormone that controls phosphate handling.","description":"Ferric carboxymaltose increased biologically active FGF23 in the substudy; the mean within-person increase at the week-two peak was approximately 303%, versus 10% with ferumoxytol.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6edbc5a6-fcb5-516d-9c86-66950a8984b3","slug":"fgf23","display_name":"Fibroblast growth factor 23 / FGF23","entity_type_key":"protein"},"role":"measured_hormone","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"860ceb18-87bd-578a-b74b-161515ac7af9","slug":"ferumoxytol","display_name":"Ferumoxytol","entity_type_key":"chemical_species"},"role":"comparator","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"3f2beafe-a8b7-5242-ab5a-7e46ee7b9913","slug":"ferric-carboxymaltose","display_name":"Ferric carboxymaltose","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"fe53ea97-98c6-5545-a40f-d4e43129d32d","slug":"circulating-intact-fgf23","display_name":"Circulating biologically active intact FGF23","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"nutrient_deficiency","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/iron-research/30518682.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257\", \"start_char\": 0, \"end_char\": 2371, \"text_sha256\": \"489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Double-blind randomized comparison with physiological substudy","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"One treatment course of ferric carboxymaltose versus ferumoxytol; five-week follow-up","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Formulation-specific pharmacological effect, not dietary iron or all intravenous iron. Trial funded by ferumoxytol manufacturer; mineral associations support but do not individually prove every causal arrow.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Iron research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"iron","display_name":"Iron","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"1997 adults with iron-deficiency anemia; 185 in substudy","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The treatment changed a hormone that controls phosphate handling.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[iron-p30518682] Randomized trial of intravenous iron-induced hypophosphatemia. (2018). https://pubmed.ncbi.nlm.nih.gov/30518682/ DOI: 10.1172/jci.insight.124486","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Blood and renal phosphate handling","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"nutrient_deficiency","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"4a38740a-0898-5760-8baf-5eee3464471b","evidence_kind":"source_excerpt","locator":"Lines 953-964","start_line":953,"end_line":964,"excerpt":"### iron-fcm-intact-fgf23\nFerric carboxymaltose increased biologically active FGF23 in the substudy; the mean within-person increase at the week-two peak was approximately 303%, versus 10% with ferumoxytol.\nCondition category: nutrient_deficiency\nnutrient_topic: Iron research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The treatment changed a hormone that controls phosphate handling.\norganism: 1997 adults with iron-deficiency anemia; 185 in substudy\ntissue_or_cell_type: Blood and renal phosphate handling\nexperimental_model: Double-blind randomized comparison with physiological substudy\nlimitations: Formulation-specific pharmacological effect, not dietary iron or all intravenous iron. Trial funded by ferumoxytol manufacturer; mineral associations support but do not individually prove every causal arrow.\nexposure: One treatment course of ferric carboxymaltose versus ferumoxytol; five-week follow-up\nevidence_span: {\"source_cache\": \"artifacts/iron-research/30518682.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257\", \"start_char\": 0, \"end_char\": 2371, \"text_sha256\": \"489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257\"}\n[iron-p30518682] Randomized trial of intravenous iron-induced hypophosphatemia. (2018). https://pubmed.ncbi.nlm.nih.gov/30518682/ DOI: 10.1172/jci.insight.124486","model_system":"Double-blind randomized comparison with physiological substudy","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [iron-p30518682] Randomized trial of intravenous iron-induced hypophosphatemia. (2018). https://pubmed.ncbi.nlm.nih.gov/30518682/ DOI: 10.1172/jci.insight.124486","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"1560864c-91d1-58dc-90c4-49bf61aba3de","stable_key":"import-e13b03e1-a614-543a-ac1b-97df18cfe30d","title":"Iron: absorption, trafficking, iron-dependent enzymes and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f9dab767a21c9bbfef3227707fe3c82953536bb1335599dd4ef93b5ea2dbf03f","revision_id":"77700d7f-2902-54b9-adae-8cbc77b24682","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}